rs61749454
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM1PM5BP4_Moderate
The ENST00000370225.4(ABCA4):āc.2966T>Cā(p.Val989Ala) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.000153 in 1,614,202 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. V989I) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000370225.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ABCA4 | NM_000350.3 | c.2966T>C | p.Val989Ala | missense_variant | 20/50 | ENST00000370225.4 | NP_000341.2 | |
ABCA4 | XM_047416704.1 | c.2744T>C | p.Val915Ala | missense_variant | 19/49 | XP_047272660.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ABCA4 | ENST00000370225.4 | c.2966T>C | p.Val989Ala | missense_variant | 20/50 | 1 | NM_000350.3 | ENSP00000359245 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000821 AC: 125AN: 152192Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000239 AC: 60AN: 251494Hom.: 0 AF XY: 0.000162 AC XY: 22AN XY: 135920
GnomAD4 exome AF: 0.0000835 AC: 122AN: 1461892Hom.: 0 Cov.: 32 AF XY: 0.0000715 AC XY: 52AN XY: 727246
GnomAD4 genome AF: 0.000821 AC: 125AN: 152310Hom.: 0 Cov.: 32 AF XY: 0.000913 AC XY: 68AN XY: 74478
ClinVar
Submissions by phenotype
not provided Pathogenic:3Uncertain:1Other:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Sep 18, 2024 | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 15161829, 22863181, 19406377, 35120629, 31964843, 32307445, 32531858, 11328725, 14517951, 25066811, 16123440, 12397427, 29126757, 29925512, 24550365, 28327576, 31980526, 32581362, 35119454, 35076026, 22247458, 11527935) - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | This sequence change replaces valine, which is neutral and non-polar, with alanine, which is neutral and non-polar, at codon 989 of the ABCA4 protein (p.Val989Ala). This variant is present in population databases (rs61749454, gnomAD 0.3%). This missense change has been observed in individual(s) with ABCA4-related retinal disease (PMID: 22247458, 23755871, 25066811, 28327576; Invitae). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 99180). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ABCA4 protein function with a positive predictive value of 95%. This variant disrupts the p.Val989 amino acid residue in ABCA4. Other variant(s) that disrupt this residue have been observed in individuals with ABCA4-related conditions (PMID: 29641573), which suggests that this may be a clinically significant amino acid residue. For these reasons, this variant has been classified as Pathogenic. - |
Uncertain significance, flagged submission | clinical testing | Eurofins Ntd Llc (ga) | Feb 22, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Sep 01, 2018 | - - |
not provided, no classification provided | literature only | Retina International | - | - - |
Retinal dystrophy Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics, Univ. Regensburg, Univ. Regensburg | Jan 01, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Aug 16, 2019 | - - |
Severe early-childhood-onset retinal dystrophy Pathogenic:1
Likely pathogenic, no assertion criteria provided | research | NIHR Bioresource Rare Diseases, University of Cambridge | Jan 01, 2015 | - - |
ABCA4-related disorder Pathogenic:1
Pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Sep 06, 2024 | The ABCA4 c.2966T>C variant is predicted to result in the amino acid substitution p.Val989Ala. This variant has been reported many times in the compound heterozygous state in individuals with Stargardt disease or ABCA4-related retinal disease (see for examples Briggs et al. 2001. PubMed ID: 11527935; Cideciyan et al. 2012. PubMed ID: 22247458; Lee et al. 2017. PubMed ID: 28327576). This variant is relatively common in some populations, with the highest allele frequency being 0.30% in individuals of African descent as reported in gnomAD. This variant has been classified as pathogenic by multiple independent submitters to the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/99180/). Given all the evidence, we too interpret c.2966T>C (p.Val989Ala) as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at